(Q36107235)

12 August 2017

1 reference

title

Mitoxantrone (Novantrone) in multiple sclerosis: new insights (English)

1 reference

12 August 2017

3

Hans-Peter Hartung

1 reference

12 August 2017

2

Bernd C Kieseier

1 reference

12 August 2017

Oliver Neuhaus

1

1 reference

12 August 2017

publication date

1 January 2004

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

12 August 2017

published in

1 reference

12 August 2017

volume

4

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

17-26

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

12 August 2017

1 reference

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

Axon pathology in neurological disease: a neglected therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

Therapeutic developments in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

Mitoxantrone: a new anticancer drug with significant clinical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

Mitoxantrone (novantrone): a review of experimental and early clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

Pharmacokinetics and metabolism of mitoxantrone. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

Suppression of experimental allergic encephalomyelitis by mitoxantrone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

Mitoxantrone in progressive multiple sclerosis: when and how to treat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

Mitoxantrone immunotherapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

Acute Myelogenous Leukemia Following Xmitoxantrone Treatment for Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.1.17

21 January 2018

Identifiers

DOI

10.1586/14737175.4.1.17

1 reference

12 August 2017

1 reference